Avalyn Pharma (NASDAQ:AVLN) Stock Price Target Cut by Morgan Stanley

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) had its price target decreased by Morgan Stanley from $57.00 to $53.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 89.83% from the company’s current price.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Avalyn Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Finally, Raymond James Financial initiated coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Avalyn Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $59.20.

Check Out Our Latest Report on AVLN

Avalyn Pharma Stock Performance

Avalyn Pharma stock opened at $27.92 on Monday. The company has a current ratio of 25.76, a quick ratio of 25.76 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $28.32. The stock has a market cap of $1.24 billion and a P/E ratio of -1.22. Avalyn Pharma has a fifty-two week low of $22.24 and a fifty-two week high of $40.17.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). As a group, analysts predict that Avalyn Pharma will post -3.87 EPS for the current fiscal year.

Insider Activity at Avalyn Pharma

In other news, insider Fmr Llc sold 53,454 shares of the company’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total value of $1,614,845.34. Following the sale, the insider owned 2,056,081 shares in the company, valued at $62,114,207.01. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma during the 2nd quarter worth approximately $82,402,000. Braidwell LP purchased a new position in shares of Avalyn Pharma during the 2nd quarter valued at approximately $26,382,000. Soleus Capital Management L.P. increased its holdings in shares of Avalyn Pharma by 143.2% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company’s stock valued at $29,031,000 after purchasing an additional 600,000 shares in the last quarter. State Street Corp acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at $10,501,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at $1,321,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.

Recommended Stories

Analyst Recommendations for Avalyn Pharma (NASDAQ:AVLN)

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.